Cellectis SA

Change company Symbol lookup

Select an option...

CLLS Cellectis SA

LAUR Laureate Education Inc

DUOT Duos Technologies Group Inc

BCLI Brainstorm Cell Therapeutics Inc

EEX Emerald Holding Inc

JPM-L JPMorgan Chase & Co

SBFM Sunshine Biopharma Inc

SEKEY Seiko Epson Corp

PXMD PaxMedica Inc

CDT Conduit Pharmaceuticals Inc

Go

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

ADR Fees

American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees